Distributes and manufactures medical imaging equipment, ophthalmic and oncology diagnostics for the Indian market. Won a major purchase order from the Central Medical Services Society, under the Ministry of Health and Family Welfare, Government of India, for Flat Panel Detectors with two batteries, routers, hard travel cases and X-Ray Generators, to be supplied in tranches by September 30, 2026. Has a Semi Knocked Down (SKD) manufacturing agreement with US-based Sonomed Escalon to assemble and eventually fully manufacture ophthalmic ultrasound devices (A-scan and pachymetry) in India for exclusive sale in the Indian market. Has signed a C-ARM development and supply deal with GBT Korea for x-ray generators, electronic control systems and C-ARM imaging devices used in orthopaedic, trauma and cardiovascular surgeries. Acquired Lifesenz Cancer Research Labs for Rs. 19.99 crore, entering precision oncology with 3D cancer cell models used to test drug effectiveness before therapy. Materials are the dominant cost at 81.1% of revenue. Listed on BSE under the SME platform (scrip code 543916). AR · MarketPing reader · 2026-08-02
Revenue streams, as the annual report describes them. Medical imaging equipment supply, Ophthalmic diagnostic devices, Cancer research and diagnostics, Pharmaceutical distribution. Trading, assembly and local manufacturing of medical imaging and diagnostic devices
| ₹ crore · consolidated | FY25 | FY26 |
|---|---|---|
| Revenue | 107 | 232 |
| EBITDA (ex other income) | — | — |
| margin % | — | — |
| Owners' profit | — | — |
| EPS, as reported (₹) | 7.70 | 15.39 |
| ROE % · ROCE % | — · 14.6 | — · 19.5 |
| Debt / equity (x) | — | — |
| Cash from operations | 9 | (32) |
| Capex | (38) | (2) |
| ₹ crore | Q4 FY25 | Q2 FY26 | Q4 FY26 |
|---|---|---|---|
| Revenue | 58 | 65 | 167 |
| Profit before tax | 6 | 7 | 16 |
| Net profit | — | — | — |
| EPS (₹) | 4.65 | 5.15 | 10.24 |
| Company | M.cap ₹ cr | P/E | P/B | EV/EBITDA | ROE % | ROCE % | Rev CAGR 5y % | EBITDA m. % |
|---|---|---|---|---|---|---|---|---|
| POLY MEDICURE LIMITED | 17,626 | 55.9 | 5.60 | 32.3 | 10.2 | 12.6 | 19.0 | 30.2 |
| FISCHER MEDICAL VENTURE L | 2,353 | 15.0 | 6.11 | 43.6 | 8.1 | 11.3 | — | 15.5 |
| TARSONS PRODUCTS LIMITED | 1,657 | 149.0 | 2.61 | 14.3 | 2.3 | 2.4 | — | 29.0 |
| LAXMI DENTAL LIMITED | 1,121 | 36.0 | 4.59 | 24.1 | 11.8 | 11.0 | — | 22.3 |
| FABTECH TECHNOLOGIES LTD | 650 | 10.6 | 1.55 | 10.6 | 9.1 | 10.7 | — | 9.9 |
| Hemant Surgical Industries Lim ◆ | 613 | 23.4 | — | — | — | 16.7 | — | — |
| Prevest Denpro Limited | 489 | 16.5 | — | — | — | 21.9 | — |
| Date · filing | Category | Importance | 1-day % | 5-day % |
|---|---|---|---|---|
| 5 Sept 2026 · Newspaper publication of 37th AGM notice and remote e-voting information | compliance | minimal | — | — |
| 4 Sept 2026 · AGM notice sent to shareholders without registered email addresses | compliance | minimal | — | — |
| 4 Sept 2026 · 37th AGM notice and FY26 annual report filed | board shareholder meetings | low | — | — |
| 4 Sept 2026 · 37th AGM scheduled for Sep 29, 2026 via video conferencing | board shareholder meetings | low | — | — |
| 31 Aug 2026 · Newspaper ad published for 37th AGM notice to be held on Sep 29, 2026 | compliance | minimal | — | — |
| 29 Aug 2026 · Board approves Directors Report; 37th AGM set for September 29, 2026 via video conferencing | board shareholder meetings | low | — | — |
| 10 Jul 2026 · Reg 74(5) Certificate - Q1 FY27 Compliance Filing | compliance | minimal | — | — |
| 9 Jun 2026 · In continuation to disclosure dated March 31, 2026, minor modification have been made in attached disclosure. | strategic transactions | medium | — | — |
| 9 Jun 2026 · Please find enclosed Press Release being issued by the Company titled "Hemant Surgical Strengthens Healthcare Portfolio through Strategic Acquisition of Majority Stake in Lifesenz Cancer .... | strategic transactions | high | — | — |
| 1 Jun 2026 · With reference to intimation dated May 27, 2026, the Company has completed the acqusition of Lifesenz Cancer Labs Private Limited and has become subsidiary of the Company w.e.f. June 01, 2026. | strategic transactions | medium | — | — |
| — |
| NURECA LIMITED | 318 | 65.2 | 1.76 | 38.3 | 1.2 | 2.7 | (7.2) | 13.0 |
| Metric | Company | Group median | Rank | Better than |
|---|---|---|---|---|
| P/E (TTM) | 23.4 | 20.0 | 11 of 17 | 38% |
| ROCE | 16.7 | 11.3 | 5 of 17 | 75% |
| Market cap | 613 | 175 | 6 of 17 | 69% |
| Where a broker report shows | This document shows | Why |
|---|---|---|
| A rating (BUY / ADD / REDUCE / SELL) | A state: the latest filed quarter and the measured reactions | an event is a fact; a rating is an opinion that requires SEBI RA registration |
| A target price and upside | The current price and the multiples against the group | a target is a forecast; a multiple is a measurement |
| Estimate years marked E | More audited years; no estimates | MarketPing publishes no forecasts — your own model lives on the Models page |
This document is a statistical summary of publicly filed information and market data, prepared by software from primary sources: SEBI results XBRL filed with BSE and NSE, LODR disclosures, shareholding patterns, exchange price data. It contains no research recommendation, no price target and no opinion on the merits of any security, and is not a research report within the meaning of the SEBI (Research Analysts) Regulations, 2014, Regulation 2(1)(w)(vii). Financial statements are as filed (consolidated where the company files consolidated results). Ratios are computed over filed lines. Where a figure is unavailable the table shows a dash rather than an estimate. The business brief is written by MarketPing's reader from the annual report and checked against it; no figure in a table was generated by a model. Nothing here constitutes investment advice, an offer or a solicitation; readers should consult a SEBI-registered adviser before acting. MarketPing is not a SEBI-registered intermediary.
